Atrasentan (ABT-627) is a selective endothelin receptor antagonist.
Atrasentan
Right!
Atrasentan (ABT-627) is a selective endothelin receptor antagonist.
- Name
- Atrasentan
- Name
- atrasentan, ABT-627
- Types of
- Selective endothelin receptor antagonist
Atrasentan
In the phase III clinical trial of 809 patients with metastatic AIPC, although the oral atrasentan group had certain advantages in the decline in quality of life score, pain score, alkaline phosphatase, and PSA, there was no statistical difference in the time to disease progression . Due to its cardiovascular toxicity, the drug has not been approved for use. Another endothelin A receptor antagonist, ZD4054, is currently undergoing a phase II clinical study. A phase III clinical trial of DOC in combination with atrasentan for AIPC is also ongoing.
